Dear Doctor Letter (Rote-Hand-Brief) on Pradaxa® (dabigatran etexilate): Necessity of monitoring renal function
2011.10.27
Active substance: dabigatran etexilate
Summaries of Product Characteristics and reference material for physicians extended to include information on the necessity of determining the creatinine clearance prior to beginning treatment as well as of further control of renal function.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN